Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes

摘要

AimsTo investigate the association of novel oral glucose‐lowering drugs (GLDs), compared with that of insulin, with risk of all‐cause mortality, cardiovascular disease (CVD) and severe hypoglycaemia.